Abstract

Knockdown of Annexin A7 (ANXA7) or C-Jun N-terminal kinase (JNK) inhibits the proliferation, migration, invasion, and lymphatic adhesion of hepatocellular carcinoma (HCC) cells, suggesting that ANXA7 and JNK signaling pathways contribute to HCC growth and lymph node metastasis (LNM). While the intervening molecular pathways are largely unknown, emerging evidence suggests that long noncoding RNAs (lncRNAs) participate in ANXA7 and JNK signaling. To identify potential therapeutic targets for HCC, we screened for lncRNAs differentially expressed among Hca-P cells stably expressing shRNA-ANXA7, shRNA-JNK, or control-shRNA. RNA sequencing identified 216 lncRNAs differentially expressed between shRNA-ANXA7 and control-shRNA cells, of which 101 were downregulated and 115 upregulated, as well as 436 lncRNAs differentially expressed between shRNA-JNK and control-shRNA cells, of which 236 were downregulated and 200 upregulated. Fifty-six lncRNAs were differentially expressed under both ANXA7 and JNK knockdown. We selected 4 of these for verification based on putative involvement in cancer regulation according to GO and KEEG analyses of target genes. Knockdown of ANXA7 or JNK suppressed expression of NONMMUT012084.2, NONMMUT024756.2, and ENSMUST00000130486, and enhanced expression of ENSMUST00000197932. These lncRNAs are intriguing candidate targets for mechanistic analysis of HCC progression and therapeutic intervention.

Highlights

  • Hepatocellular carcinoma (HCC) is the fifth most frequent cancer globally [1] and the most frequent malignant liver tumor [2]

  • 216 long noncoding RNAs (lncRNAs) were differentially expressed between shRNA-Annexin A7 (ANXA7) and control-shRNA Hca-P cell lines, with 115 upregulated and 101 downregulated, and 436 lncRNAs were differentially expressed between shRNA-Jun N-terminal kinase (JNK) and control-shRNA cells, with 200 upregulated and 236 downregulated

  • Long noncoding RNAs are involved in multiple cellular processes including gene dosage compensation, epigenetic regulation, the cell cycle, and differentiation [34], and dysregulation of lncRNA pathways modulating these processes underlies several human disorders caused by chromosomal deletions and translocations

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the fifth most frequent cancer globally [1] and the most frequent malignant liver tumor [2]. Both HCC morbidity and mortality continue to increase [3], so novel treatment strategies are urgently required. Annexin A7, termed ANXA7 or synexin, is ubiquitously expressed in the liver as 47 kDa and 51 kDa isoforms [6]. It is a Ca2+/phospholipid-binding protein that facilitates membrane aggregation, fusion, adhesion, and transport. Numerous studies have suggested that ANXA7 is a promoter of mouse HCC lymphatic metastasis [8,9,10] as downregulation suppresses the growth, differentiation, proliferation, secretion, invasion, and migration of HCC cells while enhancing apoptosis [6, 11,12,13,14]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call